Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma

Inclusion Criteria: Patients with primary, previously untreated, histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, Stage I-2, II-B, III-B, IV-A. Patients with negative, non-suspicious para-aortic nodes determined by lymphangiogram, CT, MRI or lymphadenectomy. Patients with adequate bone marrow function: ANC greater than or equal to 1,500/mcl, platelets greater than or equal to 100,000/mcl, and Hemoglobin > 10 mg/dl. Patients with adequate renal function: Creatinine equal to or less than 1.5 mg%. Patients with adequate hepatic function: Bilirubin less than or equal to 1.5 x normal and SGOT and Alkaline phosphatase less than or equal to 3 x normal. Patients who have signed an approved informed consent. Patients with GOG Performance Status of 0, 1, 2, or 3. Patients of childbearing potential must have a negative serum pregnancy test and use an effective form of contraception. Patients who are suitable for treatment with radical intent using concurrent cisplatin and pelvic radiation. Exclusion Criteria: Patients who cannot be or have not been adequately clinically staged. Patients with lower one-third vaginal involvement. Patients with septicemia or severe infection. Patients with circumstances that will not permit completion of the study or required follow-up. Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy. Patients with carcinoma of the cervical stump. Patients who are lactating or pregnant.